After completing a preclinical study, Olathe-based Flow Forward Medical nabbed another round of capital for its vascular device.
The firm raised another $1 million from a group of unnamed, individual investors, bringing the firm’s total raised to $7 million.
Flow Forward created the AFE blood pump system, which is designed for temporary use to quickly dilate peripheral veins through flow-mediated vascular remodeling prior to arteriovenous fistula surgery. In addition to mitigating care costs, the device reduces morbidity and mortality in hemodialysis patients.
CEO Nick Franano said that there are more than 2.3 million people worldwide on hemodialysis who depend on a vascular access site to receive his firm’s treatment. Franano added that the new funding provides Flow Forward with the resources to continue the development and testing of the AFE System.
The firm also recently completed a preclinical study and computational fluid dynamics study of its Arteriovenous Fistula Eligibility system.
Flow Forward is a spinoff of Franano’s previous company, Novita Therapeutics. To learn more on Flow Forward and its device, click here.